News | Deep Vein Thrombosis (DVT) | November 21, 2022

Four Prospective, Multicenter Studies Support Use of Drug-Coated Balloons Over Bare Metal Stents in Treating Femoropopliteal Lesions

New research published in Journal of the American College of Cardiology

UH Cleveland Medical Center. Image courtesy of University Hospitals

UH Cleveland Medical Center. Image courtesy of University Hospitals


November 21, 2022 —  New research published in the Journal of the American College of Cardiology shows the use of drug-coated balloons is an optimal approach compared to bare metal stents in treating femoropopliteal lesions. 

In the paper entitled “Drug-coated Balloons versus Bare Metal Stents in Femoropopliteal Lesions: Three-Year Results of Prospective, Multicenter Studies” researchers reported outcomes testing drug-coated balloons (DCB) versus bare metal stents (BMS) in a propensity-adjusted, pooled analysis of four prospective, multicenter trials. 

“While stents provide immediate scaffolding and excellent periprocedural luminal gain in femoropopliteal artery lesions, in-stent restenosis can worsen outcomes and challenge subsequent treatment,” said lead author Mehdi Shishehbor, DO, MPH, PhD, President of University Hospitals Harrington Heart & Vascular Institute, and Angela and James Hambrick Chair in Innovation. “Endovascular treatment of femoropopliteal artery disease has shifted toward drug-coated balloons, but there wasn’t much data available regarding the safety and efficacy of this approach compared to bare metal stents.” 

The primary analysis included 771 patients, 288 treated with DCB and 483 treated with BMS. The IPTW-adjusted Kaplan-Meier estimates of 12-month primary patency was 90 percent for DCB and 80 percent for BMS. DCB fare better for clinically driven target lesion revascularization at 85 percent compared to 73 percent with BMS. DCB had a 25 percent cumulative incidence of 36-month major adverse events (MAE) while BMS had 38 percent. There were no statistically significant differences observed in all-cause mortality, target limb major amputation, or thrombosis through 36 months. 

With significantly higher 12-month patency and freedom from 36-month clinically driven reintervention and MAE, and no statistically significant differences in 36-month all-cause mortality, amputation, or thrombosis observed, these results support the use of DCB over BMS in femoropopliteal lesions amenable to both treatments. 

“This research clearly shows what approach will have the most success in our patients which is what we set out to discover,” said Dr. Shishehbor. 

“Drug-coated Balloons versus Bare Metal Stents in Femoropopliteal Lesions:  Three-Year Results of Prospective, Multicenter Studies” is available to read in its entirety in the Nov. 1, 2022 online issue of Journal of the American College of Cardiology. 

For more information: UHhospitals.org 


Related Content

News | Heart Failure

June 2, 2023 — The Lundquist Institute (TLI) announced today that Jerome Rotter, MD, and Matthew Budoff, MD, two of TLI ...

Home June 02, 2023
Home
News | Heart Failure

June 2, 2023 — Dr. Philip Cardiff, Associate Professor at University College Dublin's School of Mechanical and Materials ...

Home June 02, 2023
Home
News | Heart Failure

May 25, 2023 — New data presented from an investigator-sponsored European trial found managing indicated1 heart failure ...

Home May 26, 2023
Home
News | Heart Failure

May 23, 2023 — Sacubitril/valsartan leads to greater reduction in plasma NT-proBNP levels compared to valsartan alone ...

Home May 23, 2023
Home
News | Heart Failure

May 23, 2023 — The diagnosis of heart failure is usually missed, denying patients treatments that could improve ...

Home May 23, 2023
Home
News | Heart Failure

May 23, 2023 — The first investigator-initiated study of remote pulmonary artery pressure monitoring has found that it ...

Home May 23, 2023
Home
News | Heart Failure

April 25, 2023 — Windtree Therapeutics, Inc., a biotechnology company focused on advancing late-stage interventions for ...

Home April 25, 2023
Home
News | Heart Failure

April 21, 2023 — A recent study using mice has revealed a way to turn back the clock after heart attack. The researchers ...

Home April 21, 2023
Home
News | Heart Failure

April 21, 2023 — Black adults with heart failure (HF) are more likely to die than white adults with the same condition ...

Home April 21, 2023
Home
News | Heart Failure

April 20, 2023 — The American College of Cardiology (ACC) has recognized seven Hackensack Meridian Health medical ...

Home April 20, 2023
Home
Subscribe Now